You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Details for New Drug Application (NDA): 207931

✉ Email this page to a colleague

« Back to Dashboard

NDA 207931 describes TECHNIVIE, which is a drug marketed by Abbvie and is included in one NDA. There are six patents protecting this drug. Additional details are available on the TECHNIVIE profile page.

The generic ingredient in TECHNIVIE is ombitasvir; paritaprevir; ritonavir. Additional details are available on the ombitasvir; paritaprevir; ritonavir profile page.

Summary for 207931

Tradename:	TECHNIVIE
Applicant:	Abbvie
Ingredient:	ombitasvir; paritaprevir; ritonavir
Patents:	6

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 207931

Generic Entry Date for 207931^: ⤷ Start Trial* Constraining patent/regulatory exclusivity: 8,691,938 Dosage: TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	TABLET;ORAL			Strength	12.5MG;75MG;50MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Approval Date:	Jul 24, 2015	TE:		RLD:	Yes
Patent:	8,420,596*PED	Patent Expiration:	Oct 10, 2031	Product Flag?		Substance Flag?		Delist Request?	Y
Patent:	8,642,538	Patent Expiration:	Sep 10, 2029	Product Flag?	Y	Substance Flag?	Y	Delist Request?
Patented Use:	TREATMENT OF HCV INFECTION USING PARITAPREVIR
Patent:	8,686,026	Patent Expiration:	Jun 9, 2031	Product Flag?	Y	Substance Flag?		Delist Request?

Expired US Patents for NDA 207931

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015	6,037,157*PED	⤷ Start Trial
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015	8,399,015*PED	⤷ Start Trial
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015	6,703,403*PED	⤷ Start Trial
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015	8,268,349*PED	⤷ Start Trial
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015	7,364,752*PED	⤷ Start Trial
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015	7,148,359*PED	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.